What antibody is associated with Inclusion Body Myositis (IBM)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Antibodies Associated with Inclusion Body Myositis (IBM)

Anti-cytosolic 5'-nucleotidase 1A (anti-cN1A) antibodies are the primary antibodies associated with Inclusion Body Myositis (IBM). 1, 2

Anti-cN1A Antibodies in IBM

  • Anti-cN1A (also known as anti-Mup44) antibodies represent the first identified serological biomarker specific for sporadic IBM 1
  • These antibodies target cytosolic 5'-nucleotidase 1A protein and are found in approximately 33% of IBM patients 1
  • High reactivity of anti-cN1A antibodies is 34% sensitive and 98% specific for IBM diagnosis 2
  • Moderate reactivity of anti-cN1A antibodies is 70% sensitive and 92% specific for IBM diagnosis 2

Diagnostic Value and Limitations

  • Anti-cN1A antibodies accumulate in perinuclear regions and rimmed vacuoles in IBM muscle, localizing to areas of myonuclear degeneration 2
  • These antibodies may provide a link between IBM's dual processes of autoimmunity and myodegeneration 2
  • While highly specific among muscle diseases, anti-cN1A antibodies are not 100% specific for IBM 3
  • The specificity of anti-cN1A for IBM drops from 96% to 70% in patients who also have Sjögren's syndrome 4

IBM Pathophysiology and Other Antibodies

  • IBM is characterized by CD8+ cytotoxic T cells and macrophages in the endomysium that surround and invade nonnecrotic muscle fibers expressing MHC class I 5
  • Muscle degeneration in IBM shows rimmed vacuoles, nuclear and cytoplasmic inclusions, congophilic amyloid deposits, and phosphorylated tau proteins 5
  • Unlike other inflammatory myopathies, IBM is increasingly considered a degenerative myopathy with inflammatory features 5
  • Proinflammatory cytokines including type 1 interferons (α/β) and TNF-α circulate in IBM 5

Clinical Implications

  • IBM is not associated with increased cancer risk, unlike other inflammatory myopathies 5
  • Cancer screening is not routinely required in patients with verified IBM 5
  • IBM is more common in patients with Sjögren's syndrome than in those without it (24% vs. 6%) 4
  • IBM can co-occur with other conditions such as HIV or hepatitis C, which are associated with premature immune cell exhaustion 6

Diagnostic Considerations

  • Careful clinical, electrophysiologic, and histopathologic correlation is required when evaluating patients with neuromuscular weakness and positive anti-cN1A antibodies 3
  • Anti-cN1A antibodies have been reported in other conditions including motor neuron disease, making clinical correlation essential 3
  • IBM typically does not respond to treatment, regardless of whether patients have associated Sjögren's syndrome 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.